JP2011162558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011162558A5 JP2011162558A5 JP2011110047A JP2011110047A JP2011162558A5 JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5 JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011110047 A JP2011110047 A JP 2011110047A JP 2011162558 A5 JP2011162558 A5 JP 2011162558A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- galnac4st
- c6st
- test compound
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011110047A JP5481426B2 (ja) | 2007-12-27 | 2011-05-17 | 糖鎖関連遺伝子、およびその利用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007336518 | 2007-12-27 | ||
| JP2007336518 | 2007-12-27 | ||
| JP2011110047A JP5481426B2 (ja) | 2007-12-27 | 2011-05-17 | 糖鎖関連遺伝子、およびその利用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010173610A Division JP4751956B2 (ja) | 2007-12-27 | 2010-08-02 | 糖鎖関連遺伝子、およびその利用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011162558A JP2011162558A (ja) | 2011-08-25 |
| JP2011162558A5 true JP2011162558A5 (enExample) | 2013-02-14 |
| JP5481426B2 JP5481426B2 (ja) | 2014-04-23 |
Family
ID=40823968
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547912A Active JP4585611B2 (ja) | 2007-12-27 | 2008-12-26 | 糖鎖関連遺伝子、およびその利用 |
| JP2010173610A Active JP4751956B2 (ja) | 2007-12-27 | 2010-08-02 | 糖鎖関連遺伝子、およびその利用 |
| JP2011110047A Active JP5481426B2 (ja) | 2007-12-27 | 2011-05-17 | 糖鎖関連遺伝子、およびその利用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009547912A Active JP4585611B2 (ja) | 2007-12-27 | 2008-12-26 | 糖鎖関連遺伝子、およびその利用 |
| JP2010173610A Active JP4751956B2 (ja) | 2007-12-27 | 2010-08-02 | 糖鎖関連遺伝子、およびその利用 |
Country Status (7)
| Country | Link |
|---|---|
| US (6) | US20110027248A1 (enExample) |
| EP (4) | EP3360556B1 (enExample) |
| JP (3) | JP4585611B2 (enExample) |
| KR (6) | KR20100111282A (enExample) |
| CN (2) | CN103656644A (enExample) |
| SG (2) | SG10202001748VA (enExample) |
| WO (1) | WO2009084232A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2685636T3 (es) * | 2007-06-29 | 2018-10-10 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Método de fijación y expresión de sustancia fisiológicamente activa |
| CN102548393B (zh) * | 2009-07-31 | 2015-06-03 | 斯特里克再生医学学院,斯特里克学院事务所 | 脂肪性肝炎-肝癌模型动物 |
| IN2014MN00908A (enExample) | 2011-11-18 | 2015-04-17 | Nitto Denko Corp | |
| US20150337313A1 (en) * | 2012-07-17 | 2015-11-26 | Stelic Institute & Co. | Mucosal healing promoter |
| PL2992098T3 (pl) * | 2013-05-01 | 2019-09-30 | Ionis Pharmaceuticals, Inc. | Kompozycje i sposoby modulowania ekspresji hbv i ttr |
| JP6302183B2 (ja) * | 2013-07-12 | 2018-03-28 | 株式会社エンザミン研究所 | アディポサイトカイン産生バランス調整剤及び脂肪組織の炎症・酸化ストレス抑制剤並びに脂肪組織のマクロファージ浸潤抑制剤 |
| EP3265567B1 (en) | 2015-03-02 | 2020-07-29 | Conagen Inc. | Regulatory elements from labyrinthulomycetes microorganisms |
| WO2017078054A1 (ja) | 2015-11-04 | 2017-05-11 | 株式会社ステリック再生医科学研究所 | ＲＮＡｉ分子とＮ－アセチル化キトサンとを含む複合体 |
| US10633454B2 (en) | 2016-11-01 | 2020-04-28 | Conagen Inc. | Expression of modified glycoproteins and glycopeptides |
| JP7129912B2 (ja) | 2016-12-07 | 2022-09-02 | 株式会社ステリック再生医科学研究所 | 慢性疾患の治療及び予防用医薬組成物 |
| CA3045944A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018183934A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
| WO2019173226A1 (en) * | 2018-03-05 | 2019-09-12 | Synthetic Genomics, Inc. | Organisms and methods for producing glycomolecules with low sulfation |
| CN109897812B (zh) * | 2019-03-19 | 2021-09-03 | 江南大学 | 一种表达软骨素4-硫酸转移酶基因的重组菌及其应用 |
| CN113811313A (zh) * | 2019-05-08 | 2021-12-17 | Tme治疗医学有限公司 | 食管狭窄抑制剂 |
| CN116254296A (zh) * | 2023-03-27 | 2023-06-13 | 中国科学院微生物研究所 | 利用昆虫细胞杆状病毒表达系统表达硫酸软骨素修饰酶的方法及应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4571242B2 (ja) * | 1996-07-24 | 2010-10-27 | 生化学工業株式会社 | ヒト由来のグリコサミノグリカンスルホトランスフェラーゼのポリペプチド及びそれをコードするｄｎａ |
| AU6897198A (en) * | 1997-04-11 | 1998-11-11 | Beth Israel Deaconess Medical Center | Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions |
| EP1839671A3 (en) * | 1999-12-02 | 2007-10-31 | BioMarin Pharmaceutical Inc. | Attenuation of fibroblast proliferation |
| CA2393186A1 (en) * | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
| US6713274B2 (en) * | 2002-05-13 | 2004-03-30 | The Regents Of The University Of California | Method for identifying modulators of sulfotransferase activity |
| EP1541580B1 (en) * | 2002-07-10 | 2013-02-27 | Seikagaku Corporation | Sulfotransferase inhibitors |
| WO2005089316A2 (en) * | 2004-03-12 | 2005-09-29 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using fxr ligands |
| WO2007049361A1 (ja) * | 2005-10-27 | 2007-05-03 | Stelic Corp. | 肝線維化抑制剤 |
| WO2008020489A1 (en) | 2006-08-17 | 2008-02-21 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Remedy for inflammatory bowel disease |
| JP4101276B2 (ja) | 2006-08-25 | 2008-06-18 | 株式会社ステリック再生医科学研究所 | 慢性閉塞性肺疾患改善剤 |
| JP2009286695A (ja) * | 2006-09-08 | 2009-12-10 | Stelic Institute Of Regenerative Medicine | 眼線維性血管新生抑制剤 |
| WO2008029493A1 (fr) * | 2006-09-08 | 2008-03-13 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Inhibiteur de dégénération de fibres nerveuses |
| ES2685636T3 (es) | 2007-06-29 | 2018-10-10 | Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. | Método de fijación y expresión de sustancia fisiológicamente activa |
-
2008
- 2008-12-26 US US12/809,969 patent/US20110027248A1/en not_active Abandoned
- 2008-12-26 KR KR1020107016694A patent/KR20100111282A/ko not_active Ceased
- 2008-12-26 KR KR1020157037089A patent/KR20160007671A/ko not_active Withdrawn
- 2008-12-26 KR KR1020167022756A patent/KR20160103554A/ko not_active Ceased
- 2008-12-26 EP EP18151424.1A patent/EP3360556B1/en active Active
- 2008-12-26 EP EP20151386.8A patent/EP3673910B1/en active Active
- 2008-12-26 EP EP15194114.3A patent/EP3045178A1/en not_active Withdrawn
- 2008-12-26 KR KR1020197037818A patent/KR102244872B1/ko active Active
- 2008-12-26 SG SG10202001748VA patent/SG10202001748VA/en unknown
- 2008-12-26 JP JP2009547912A patent/JP4585611B2/ja active Active
- 2008-12-26 EP EP08866254A patent/EP2238987A4/en not_active Withdrawn
- 2008-12-26 SG SG10201402793PA patent/SG10201402793PA/en unknown
- 2008-12-26 WO PCT/JP2008/004025 patent/WO2009084232A1/ja not_active Ceased
- 2008-12-26 CN CN201310495268.2A patent/CN103656644A/zh active Pending
- 2008-12-26 KR KR1020177023558A patent/KR101926292B1/ko active Active
- 2008-12-26 CN CN200880127570XA patent/CN101965196A/zh active Pending
- 2008-12-26 KR KR1020187034630A patent/KR20180132162A/ko not_active Ceased
-
2010
- 2010-08-02 JP JP2010173610A patent/JP4751956B2/ja active Active
-
2011
- 2011-05-17 JP JP2011110047A patent/JP5481426B2/ja active Active
-
2013
- 2013-11-08 US US14/075,919 patent/US20140128452A1/en not_active Abandoned
-
2015
- 2015-05-05 US US14/704,333 patent/US20150290238A1/en not_active Abandoned
-
2016
- 2016-07-21 US US15/216,231 patent/US20170067058A1/en not_active Abandoned
-
2019
- 2019-01-02 US US16/237,875 patent/US20190330637A1/en not_active Abandoned
-
2022
- 2022-06-03 US US17/805,290 patent/US12637675B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011037847A5 (enExample) | ||
| AU2018253580A1 (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
| AU2018260825A1 (en) | Compositions and Methods for Lowering Levels of High-Sensitivity (hs-CRP) in a Subject | |
| BR112014023898A2 (pt) | moléculas de ácido nucleico artificiais compreendendo 5''utr top | |
| WO2016176690A3 (en) | Gene therapy for autosomal dominant diseases | |
| HK1223795A1 (zh) | 拉喹莫德响应性的基因表达生物标志物 | |
| JP2012050449A5 (enExample) | ||
| EA202091568A1 (ru) | Ингибиторы глюкозилцерамид-синтазы | |
| EP2760371A4 (en) | VENTRICULAR TRANSCATHETER RECONSTRUCTION STRUCTURES, METHODS AND SYSTEMS FOR THE TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER SUFFERING | |
| BR112014015202A8 (pt) | processo para a melhor separação de uma solução orgânica hidrófoba de um meio de cultura aquoso | |
| WO2011156734A3 (en) | Method of characterizing vascular diseases | |
| WO2015048793A3 (en) | Nucleic acid biomarker and use thereof | |
| JP2009178558A5 (enExample) | ||
| WO2010019914A3 (en) | Anti-arrhythmia agents, methods of their use, methods for their identification, and kits thereofre | |
| JP2016528914A5 (enExample) | ||
| NZ624708A (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| JP2013527772A5 (enExample) | ||
| PH12014502282A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
| WO2013003899A8 (en) | Methods of treating or preventing rheumatic disease | |
| HK1206791A1 (en) | Means and methods for response prediction of hepatitis b treatment | |
| TN2012000607A1 (en) | Method for predicting a therapy response in subjects with multiple sclerosis | |
| RU2009145864A (ru) | Способ прогнозирования дизадаптации сердечной деятельности у детей, перенесших кардиохирургическую коррекцию врожденного порока сердца | |
| PH12019500738A1 (en) | Methods of preserving the biological activity of ribonucleic acids | |
| RU2017139718A (ru) | Агент, индуцирующий клеточную гибель, для клеток, имеющих мутации гена braf, агент, подавляющий рост для таких клеток, и фармацевтическая композиция для терапии заболеваний, вызванных дефектом роста таких клеток | |
| WO2012002775A3 (ko) | 뉴로필린１ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법 |